<DOC>
	<DOCNO>NCT00117039</DOCNO>
	<brief_summary>The purpose trial ass effectiveness Aranesp® administer 300 mcg every 3 week ( q3w ) achieve therapeutic objective anemia treatment ( achieve maintain hemoglobin level consistent National Comprehensive Cancer Network ( NCCN ) guideline ) .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Aranesp® Cancer Patients With Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects nonmyeloid malignancy Anemia ( Hgb le 11.0 g/dL ) due cancer chemotherapy Receiving chemotherapy expect receive least 8 additional week chemotherapy Adequate renal function Adequate liver function Subjects acute myelogenous leukemia ( AML ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome ( MDS ) Unstable cardiac disease Active bleeding Active systemic chronic infection Severe active chronic inflammatory disease Other hematologic disorder associate anemia Uncontrolled hypertension Known iron nutritional deficiency Known positive test human immunodeficiency virus ( HIV ) infection History pure red cell aplasia History positive antibody response erythropoietic agent Erythropoietin therapy within 4 week screen RBC transfusion within 2 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>anemia</keyword>
	<keyword>fatigue</keyword>
	<keyword>Aranesp®</keyword>
	<keyword>clinical trial</keyword>
</DOC>